Table 1.

Nanoparticle Formulations

Formulation Designationa	Drug Content (%)	Fenretinide (mg)	Polymer R1 (mg)b	Polymer R2 (mg)c	Polymer R3 (mg)d
R1-B	0	-	150	-	-
R1-5	5	7.89	150	-	-
R1-10	10	16.67	150	-	-
R1-20	20	37.50	150	-	-
R2-B	0	-	-	150	-
R2-5	5	7.89	-	150	-
R2-10	10	16.67	-	150	-
R2-20	20	37.50	-	150	-
R3-B	0	-	-	-	150
R3-5	5	7.89	-	-	150
R3-10	10	16.67	-	-	150
R3-20	20	37.50	-	-	150

^aB = Blank formulation; 5 = 5% drug loading; 10 = 10% drug loading; 20 = 20% drug loading

^b7,000–17,000 MW PLGA polymer ester terminated

^c7,000–17,000 MW PLGA polymer acid terminated

^ddi-block copolymer containing an ester terminated PLGA (10,000 MW) and 10% PEG (5,000 MW)